Determining the optimal second-line approach in patients with metastatic clear cell renal cell carcinoma (ccRCC) who have progressed either on 1 or 2 lines of therapy and who had ...
Caris Life Sciences reports another breakthrough study for GPSai in identifying and correcting misdiagnosis of cancer patients: Irving, Texas Monday, March 23, 2026, 16:00 Hrs [IS ...
Abstract: Accurate differentiation of lung adenocarcinoma subtypes is critical for personalized surgical strategies, particularly in intraoperative differentiation between adenocarcinoma in situ (AIS) ...
Amini: The majority of these patients — except at this time stage 1 — will need systemic therapy as part of their therapy, ...
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts ...
For oncologists navigating the rapidly evolving landscape of renal cell carcinoma (RCC), the data presented at the 2026 ASCO ...
Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster ...
Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program ...
KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, has discovered how cancer cells can ...
Immutep Limited IMMP shares are tumbling on Friday following the company’s update for the TACTI-004 Phase 3 trial. The ...
Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results